A Study of LY4268989 (MORF 057) in Healthy Participants

This study is looking for healthy volunteers, aged 18 to 65, to help understand how the body processes two different forms of an oral drug called LY4268989 (MORF 057). Researchers want to see if these two forms work similarly when taken with different meals. You would need to be generally healthy with a body mass index (BMI) between 18.0 and 32.0. The main goal is to measure how much of LY4268989 is in your blood over time (pharmacokinetics or PK), specifically the highest concentration (Cmax) and the total amount (AUC) from Day 1 to Day 18. The study involves 18 overnight stays at a clinical research unit and lasts about 9 weeks.

Study design: This is an interventional study with a planned enrollment of 50 healthy participants. The specific phase of the study is not provided.
What's involved: You would have 18 overnight stays at a clinical research unit (CRU) over approximately 9 weeks. Blood tests will be performed to check how your body processes the drug.
Compensation: Not stated in the trial record.
Follow-up: The primary measurements for the drug in your body (pharmacokinetics) will be taken from Day 1 to Day 18.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of LY4268989 (MORF 057) in Healthy Participants

Not Yet Recruiting

PHASE1Ages 18–65InterventionalBasic science

Eli Lilly and Company

~50 participants

Updated 2026-07-16 on ClinicalTrials.gov

What's tested:LY4268989

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989

Measured over Day 1 to Day 18

+1 more outcome measured

Conditions

Healthy

Where it's being run

1 sites across 1 states

Florida1

Study leadership

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

[email protected]

1-317-615-4559

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory test, electrocardiograms (ECGs), and vital signs.

Have a body mass index (BMI) within the range 18.0 to 32.0 kilogram/square meter (kg/m²), inclusive, at screening.

Exclusion

Have a current or recent acute, active infection. For at least 30 days before screening and up to Day 1, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.

Have presence of significant uncontrolled respiratory, cerebrocardiovascular, cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disorders, or abnormal laboratory values at screening that, in the opinion of the sponsor or investigator, pose an unacceptable risk to the participant if participating in the study or of interfering with the interpretation of data.

Are immunocompromised to an extent that participation in the study would pose an unacceptable risk to the participant as determined by the investigator.

Use or intend to use prescription or nonprescription medication, including dietary supplements, vitamins, herbal supplements, traditional Chinese medicine, alternative medicines, or any medication known to be moderate to strong cytochrome P450 3A4 (CYP3A) inhibitors or inducers, or organic anion transporting polypeptide 1B1 (OATP1B) inhibitors, P-gp inhibitors, or medications that are narrow therapeutic index substrates for breast cancer resistance protein (BCRP) or P-gp within 14 days or 5 half lives, whichever is longer, prior to dosing, until the end of study assessments are complete.

What this trial measures

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989Day 1 to Day 18
PK: Area Under the Concentration Curve (AUC) of LY4268989Day 1 to Day 18

Trialytics